Proactive Investors - Run By Investors For Investors

Summit Therapeutics soars as it hails potential of very early stage antibiotic

The treatment has been developed to tackle a gram-negative bacteria that is becoming resistant to current drugs
research inspecting petri dish
The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam

Summit Therapeutics PLC (NASDAQ:SMMT) (LON:SUMM) shares soared higher on Monday as the firm trumpeted the early success of a pre-clinical antibiotic that may help overcome drug resistance to a potentially deadly infection.

The group said it presented data at a leading healthcare conference that showed its treatment, DDS-04, had successfully tackled bacteria called Enterobacteriaceae in animals with urinary tract infections.

Resistant strain

Antimicrobial resistance means people contracting the gram-negative bacterial strain, which also affects the lungs and bloodstream, “are increasingly at risk for poor outcomes”, said Dr David Roblin, Summit’s head of research and development.

“Mainstay treatments are losing their effectiveness, and patients do not have the luxury of time to fail antibiotic therapy,” he explained. “There is a pressing need for new, targeted Enterobacteriaceae antibiotics that can serve to improve patient outcomes.”

The data were presented at the European Congress of Clinical Microbiology & Infectious Diseases, taking place in Amsterdam.

In early afternoon trading in London, Summit shares were 17.3% higher at 32.25p.

 -- Adds share price --

View full SUMM profile View Profile

Summit Therapeutics PLC Timeline

Related Articles

A stomach adenocarcinoma
February 12 2019
The company’s B-cell peptide cancer vaccines have shown promise in pre-clinical and early-stage study.
scientist in a lab
April 12 2019
Danish giant Novo Nordisk recently signed up to use its NDD platform, and bosses expect more collaboration deals in the coming months
consumer health segment overview
January 10 2019
The company sells clinically validated anti-ageing products for hair, skin and body.
Copyright © Proactiveinvestors.com, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use